Does the media favor CRNX or KURA?

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Kura Oncology. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 3 mentions for Kura Oncology. Crinetics Pharmaceuticals' average media sentiment score of 1.04 beat Kura Oncology's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CPRX or KURA?

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.25 beat Kura Oncology's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, TLX or KURA?

Telix Pharmaceuticals has higher revenue and earnings than Kura Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.01 -$7.12M N/A N/A Kura Oncology $71.64M 13.75 -$278.67M -$3.35 N/A

Does the media refer more to TLX or KURA?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.32 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BEAM or KURA?

In the previous week, Beam Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Kura Oncology. Beam Therapeutics' average media sentiment score of 0.10 beat Kura Oncology's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RLAY or KURA?

In the previous week, Relay Therapeutics had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Relay Therapeutics and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.00 beat Relay Therapeutics' score of -0.04 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kura Oncology (KURA) Competitors

$11.10 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$11.03 -0.07 (-0.62%)

As of 07/2/2026 06:54 PM Eastern

Compare

KURA vs. CRNX, CPRX, TLX, BEAM, and RLAY

Should you buy Kura Oncology stock or one of its competitors? MarketBeat compares Kura Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kura Oncology include Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), Telix Pharmaceuticals (TLX), Beam Therapeutics (BEAM), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does Kura Oncology compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Kura Oncology has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	578.28	-$465.32M	-$5.13	N/A
Kura Oncology	$71.64M	13.75	-$278.67M	-$3.35	N/A

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kura Oncology has a net margin of -411.19% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Kura Oncology	-411.19%	-141.95%	-43.28%

Crinetics Pharmaceuticals currently has a consensus target price of $73.78, suggesting a potential upside of 74.70%. Kura Oncology has a consensus target price of $25.46, suggesting a potential upside of 129.38%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Kura Oncology. MarketBeat recorded 7 mentions for Crinetics Pharmaceuticals and 3 mentions for Kura Oncology. Crinetics Pharmaceuticals' average media sentiment score of 1.04 beat Kura Oncology's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kura Oncology beats Crinetics Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

In the previous week, Catalyst Pharmaceuticals and Catalyst Pharmaceuticals both had 3 articles in the media. Catalyst Pharmaceuticals' average media sentiment score of 0.25 beat Kura Oncology's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Catalyst Pharmaceuticals currently has a consensus target price of $32.00, indicating a potential upside of 1.75%. Kura Oncology has a consensus target price of $25.46, indicating a potential upside of 129.38%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Kura Oncology is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Kura Oncology's net margin of -411.19%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Kura Oncology	-411.19%	-141.95%	-43.28%

Catalyst Pharmaceuticals has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$588.99M	6.54	$214.33M	$1.74	18.07
Kura Oncology	$71.64M	13.75	-$278.67M	-$3.35	N/A

Summary

Catalyst Pharmaceuticals beats Kura Oncology on 12 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Telix Pharmaceuticals currently has a consensus target price of $21.13, suggesting a potential upside of 77.97%. Kura Oncology has a consensus target price of $25.46, suggesting a potential upside of 129.38%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Telix Pharmaceuticals has a beta of -0.31, indicating that its stock price is 131% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Telix Pharmaceuticals' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Kura Oncology	-411.19%	-141.95%	-43.28%

Telix Pharmaceuticals has higher revenue and earnings than Kura Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.01	-$7.12M	N/A	N/A
Kura Oncology	$71.64M	13.75	-$278.67M	-$3.35	N/A

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.00 beat Telix Pharmaceuticals' score of -0.32 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Kura Oncology on 8 of the 13 factors compared between the two stocks.

How does Kura Oncology compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Beam Therapeutics has a net margin of -39.66% compared to Kura Oncology's net margin of -411.19%. Beam Therapeutics' return on equity of -29.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Kura Oncology	-411.19%	-141.95%	-43.28%

Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 2 more articles in the media than Kura Oncology. MarketBeat recorded 5 mentions for Beam Therapeutics and 3 mentions for Kura Oncology. Beam Therapeutics' average media sentiment score of 0.10 beat Kura Oncology's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has higher revenue and earnings than Kura Oncology. Beam Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	25.61	-$79.99M	-$0.68	N/A
Kura Oncology	$71.64M	13.75	-$278.67M	-$3.35	N/A

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 34.62%. Kura Oncology has a consensus price target of $25.46, indicating a potential upside of 129.38%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Beam Therapeutics beats Kura Oncology on 13 of the 17 factors compared between the two stocks.

How does Kura Oncology compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Relay Therapeutics has higher earnings, but lower revenue than Kura Oncology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	232.78	-$276.48M	-$1.57	N/A
Kura Oncology	$71.64M	13.75	-$278.67M	-$3.35	N/A

In the previous week, Relay Therapeutics had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Relay Therapeutics and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.00 beat Relay Therapeutics' score of -0.04 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relay Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Relay Therapeutics' return on equity of -43.94% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
Kura Oncology	-411.19%	-141.95%	-43.28%

Relay Therapeutics presently has a consensus target price of $23.30, suggesting a potential upside of 24.93%. Kura Oncology has a consensus target price of $25.46, suggesting a potential upside of 129.38%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Relay Therapeutics beats Kura Oncology on 11 of the 17 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$985.39M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-3.31	21.61	28.02	24.70
Price / Sales	13.75	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	5.55	8.66	10.96	6.46
Net Income	-$278.67M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.83%	3.39%	2.12%	1.69%
1 Month Performance	27.00%	10.81%	5.25%	3.81%
1 Year Performance	87.82%	62.61%	33.29%	23.90%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	2.2487 of 5 stars	$11.10 flat	$25.46 +129.4%	+87.8%	$985.39M	$71.64M	N/A	130	Positive News
CRNX Crinetics Pharmaceuticals	3.6116 of 5 stars	$36.94 +0.7%	$76.13 +106.1%	+41.4%	$3.87B	$7.70M	N/A	210	Analyst Forecast
CPRX Catalyst Pharmaceuticals	3.408 of 5 stars	$31.46 -0.1%	$32.00 +1.7%	+45.3%	$3.86B	$588.99M	18.08	80	News Coverage
TLX Telix Pharmaceuticals	4.5133 of 5 stars	$11.30 +6.0%	$21.13 +86.9%	-26.4%	$3.62B	$803.79M	N/A	1,184	Gap Up
BEAM Beam Therapeutics	1.9806 of 5 stars	$34.95 +0.4%	$46.83 +34.0%	+73.8%	$3.58B	$139.74M	N/A	510	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. CRNX, CPRX, TLX, BEAM, and RLAY

How does Kura Oncology compare to Crinetics Pharmaceuticals?

Summary

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Summary

How does Kura Oncology compare to Telix Pharmaceuticals?

Summary

How does Kura Oncology compare to Beam Therapeutics?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. CRNX, CPRX, TLX, BEAM, and RLAY

How does Kura Oncology compare to Crinetics Pharmaceuticals?

Which has more risk & volatility, CRNX or KURA?

Which has better valuation and earnings, CRNX or KURA?

Do institutionals & insiders hold more shares of CRNX or KURA?

Is CRNX or KURA more profitable?

Do analysts rate CRNX or KURA?

Does the media favor CRNX or KURA?

Summary

How does Kura Oncology compare to Catalyst Pharmaceuticals?

Does the media favor CPRX or KURA?

Do analysts rate CPRX or KURA?

Do institutionals & insiders hold more shares of CPRX or KURA?

Which has more volatility and risk, CPRX or KURA?

Is CPRX or KURA more profitable?

Which has preferable earnings and valuation, CPRX or KURA?

Summary

How does Kura Oncology compare to Telix Pharmaceuticals?

Do analysts recommend TLX or KURA?

Which has more risk and volatility, TLX or KURA?

Is TLX or KURA more profitable?

Which has higher valuation and earnings, TLX or KURA?

Does the media refer more to TLX or KURA?

Summary

How does Kura Oncology compare to Beam Therapeutics?

Is BEAM or KURA more profitable?

Which has more risk and volatility, BEAM or KURA?

Do insiders & institutionals have more ownership in BEAM or KURA?

Does the media favor BEAM or KURA?

Which has higher valuation & earnings, BEAM or KURA?

Do analysts prefer BEAM or KURA?

Summary

How does Kura Oncology compare to Relay Therapeutics?

Which has more volatility and risk, RLAY or KURA?

Which has stronger earnings & valuation, RLAY or KURA?

Does the media favor RLAY or KURA?

Do insiders & institutionals hold more shares of RLAY or KURA?

Is RLAY or KURA more profitable?

Do analysts recommend RLAY or KURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools